ClinicalTrials.gg
TerminatedNCT04875975Updated May 31, 2025Results posted

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

A Phase 2 interventional study of Rozanolixizumab and Placebo in Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis, sponsored by UCB Biopharma SRL. Terminated at 27 sites in 9 countries. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Autoimmune Diseases of the Nervous System with a site in United States — 7 open to participants now, 10 under way, 2 of them phase 3. Autoimmune Diseases of the Nervous System · United States.

Enrollment
18th of 21
12 · median 53
Started
2021
with 6 others
Phase 2
9 of 28
2 open now
Registered
15th of 28
by date

Among the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2021, is one of 9 in phase 2, and was the 15th registered.

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

Browse Autoimmune Diseases of the Nervous System studies →

Open to participants now

7 of the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.

03

Conditions studied

  • Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Keywords

  • Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
  • Phase 2
  • Rozanolixizumab
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥18 to ≤89 years of age
  • Study participant must be seropositive for leucine-rich glioma inactivated 1 (LGI1) antibody
  • Study participant must have ≥2 seizures/week during the Screening Period or have experienced such seizures that stopped following high dose (500 to 1000 milligram (mg) methylprednisolone (MP) equivalent/day):

    • Either faciobrachial dystonic seizures (FBDS) with or without other focal (partial) seizures including focal to bilateral tonic clonic
    • Or focal (partial) seizures including focal to bilateral tonic clonic and fulfil the following new-onset encephalitis (AIE) criteria
  • Study participant has initiated or re-initiated corticosteroids at a dose of 500 to 1000 mg MP equivalent/day within 42 days prior to randomization. Participants re-initiating corticosteroids are eligible only if re-initiation is due to seizure rebound and within the timeframe outlined. If the study participant has initiated a steroid taper, the study participant cannot receive an oral steroid dose lower than 40mg/day when randomized
  • Study participant with onset of disease symptom between 0 to 12 months prior to Screening, per investigator's assessment.
  • Study participant weighs at least 35 kg at Screening
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    i) Not a woman of (WOCBP) OR ii) A WOCBP who agrees to follow the guidance during the treatment period and for at least 90 days after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Study participant has a known to any components of the study medication or any other anti-neonatal Fc receptor (FcRn) medications.
  • Study participant has a confirmed prior diagnosis of epilepsy or new onset seizures that are unrelated to LGI1 encephalitis (AIE) or has any known or suspected medical cause for the onset of seizures other than possible AIE
  • Study participant has a known active neoplastic disease or history of neoplastic disease within 5 years of study entry
  • Study participant has renal impairment, defined as (GFR) \<30mL/min/1.73m2 at the Screening Visit
  • Study participant has a active infection (including unresolved or not adequately treated infection) as assessed by investigator, including participants with a serious infection within 6 weeks prior to the first dose of medicinal product (IMP)
  • Study participant has a history of chronic ongoing infections
  • Study participant has current unstable liver or biliary disease, per investigator assessment, defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
  • Study participant has positive tuberculosis (TB) test at the Screening Visit
  • Study participant has a history of solid organ transplant or hematopoietic stem cell transplant
  • Study participant has undergone a splenectomy
  • Study participant has a current or medical history of primary immune deficiency
  • Study participant has received a within 4 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 8 weeks following the final dose of investigational medicinal product (IMP)
  • Study participant has previously received rozanolixizumab drug product
  • (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) are >3x (ULN)
  • Study participant has a total IgG level ≤5.5 g/L at the Screening Visit
  • Study participant has \<1500 cells/mm\^3 at the Screening Visit
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab

    Participants will be randomized to receive a predefined dose of rozanolixizumab.

    Drug: Rozanolixizumab

  • Placebo comparator
    Placebo

    Participants will be randomized to receive a dose of placebo.

    Drug: Placebo

Interventions

  • * Pharmaceutical form: Solution for infusion * Route of administration: Subcutaneous use Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period.

  • DrugPlacebo

    * Pharmaceutical form: Solution for infusion * Route of administration: Subcutaneous use Subjects will receive placebo in a pre-specified sequence during the Treatment Period.

06

What researchers measure

Primary outcomes

  1. Number of Seizure Free Study Participants at the End of the Treatment

    Seizure freedom was defined as a minimum of 28 consecutive days of no seizures of any type during the treatment and maintained until the end of the treatment (Week 25).

    Time frame: From Baseline until the end of the Treatment (Week 25)

Secondary outcomes

  1. Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment

    The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of 12 subtests that contribute to 5 age-based domain index scores (immediate memory, visuospatial/constructional, language, attention, delayed memory) that were aggregated for a total scale index score. All index scores have an age-based mean of 100, with a standard deviation (SD) of 15. The total scale score was calculated by taking the mean of the sum of the five index scores. Total possible scale index scores range from 40-135. Higher scores reflect better neurocognitive performance. The total scale index score is the score typically used to reflect global neurocognitive status. Baseline of RBANS is defined as the screening (Visit 1, Week -1) value.

    Time frame: From Baseline to Week 5, 13, 21 and 25

  2. Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment

    Percentage of participants with a favorable outcome in mRS during treatment, where favorable outcome defined as no worsening for participants with Baseline mRS score of ≤1 or improvement of ≥1 point for participants with Baseline mRS score of ≥2. The mRS is commonly used scale for measuring degree of disability or dependence in daily activities of people who suffered a stroke or other causes of neurological disability. The scale ranges from 0 (perfect health) to 6 (death). 0-No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. Moderate disability; requiring some help, but able to walk without assistance 4. Moderately severe disability; unable to walk and attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead

    Time frame: From Baseline until the end of the Treatment (Week 25)

  3. Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment

    Study participants who required rescue medication due to an absence or loss of clinical benefit were discontinued blinded treatment and completed the assessments for the early discontinuation visit.

    Time frame: From Baseline until the end of the Treatment (Week 25)

  4. Time to First Occurrence of Seizure Freedom During the Treatment

    The time to first occurrence of seizure freedom was defined by the number of days after randomization to the first day of the first 28 consecutive days without seizures during the treatment. Time to first occurrence of 28 consecutive days of seizure freedom (days) during the treatment was calculated as date of first day of occurrence of 28 consecutive days of seizure freedom - Date of Randomization + 1.

    Time frame: From Baseline until the end of the Treatment (Week 25)

  5. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP, whether or not related to the IMP. A TEAE was defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsens in intensity following exposure to treatment up to the end of the Treatment and including the 8-week (56 days) Safety-Follow Up (SFU).

    Time frame: From Baseline until the End of Study (Week 32)

07

Results

Posted May 31, 2025
Limitations and caveats
Due to the early termination of the recruitment and insufficient participants, it was not feasible to carry out the statistical analyses as originally planned.

Participant flow

The study started to enroll participants in September 2021 and concluded in April 2024.

Participant flow — Overall Study
MilestonePlaceboRozanolixizumab (RLZ)
Started66
Completed20
Not completed46
Withdrew: Adverse event12
Withdrew: Lack of efficacy22
Withdrew: Permanently left due to seizure recurrence10
Withdrew: Relapse with insults01
Withdrew: Permanently left due to new seizure recurrence01

Outcome measures

PrimaryNumber of Seizure Free Study Participants at the End of the Treatment

Seizure freedom was defined as a minimum of 28 consecutive days of no seizures of any type during the treatment and maintained until the end of the treatment (Week 25).

Time frame:
From Baseline until the end of the Treatment (Week 25)
Reported as:
Count of participants · Participants
Number of Seizure Free Study Participants at the End of the Treatment
ParticipantsPlaceboRozanolixizumab (RLZ)
Number of Seizure Free Study Participants at the End of the Treatment10
SecondaryChange From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of 12 subtests that contribute to 5 age-based domain index scores (immediate memory, visuospatial/constructional, language, attention, delayed memory) that were aggregated for a total scale index score. All index scores have an age-based mean of 100, with a standard deviation (SD) of 15. The total scale score was calculated by taking the mean of the sum of the five index scores. Total possible scale index scores range from 40-135. Higher scores reflect better neurocognitive performance. The total scale index score is the score typically used to reflect global neurocognitive status. Baseline of RBANS is defined as the screening (Visit 1, Week -1) value.

Time frame:
From Baseline to Week 5, 13, 21 and 25
Reported as:
Mean · score on a scale
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment
score on a scalePlaceboRozanolixizumab (RLZ)
Week 54.5 ± 2.62.2 ± 11.3
Week 137.0 ± 2.912.3 ± 7.9
Week 217.0 ± 7.3NA ± NA
Week 25NA ± NANA ± NA
SecondaryPercentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment

Percentage of participants with a favorable outcome in mRS during treatment, where favorable outcome defined as no worsening for participants with Baseline mRS score of ≤1 or improvement of ≥1 point for participants with Baseline mRS score of ≥2. The mRS is commonly used scale for measuring degree of disability or dependence in daily activities of people who suffered a stroke or other causes of neurological disability. The scale ranges from 0 (perfect health) to 6 (death). 0-No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. Moderate disability; requiring some help, but able to walk without assistance 4. Moderately severe disability; unable to walk and attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead

Time frame:
From Baseline until the end of the Treatment (Week 25)
Reported as:
Number · percentage of participants
Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment
percentage of participantsPlaceboRozanolixizumab (RLZ)
Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the TreatmentNANA
SecondaryNumber of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment

Study participants who required rescue medication due to an absence or loss of clinical benefit were discontinued blinded treatment and completed the assessments for the early discontinuation visit.

Time frame:
From Baseline until the end of the Treatment (Week 25)
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment
ParticipantsPlaceboRozanolixizumab (RLZ)
Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment32
SecondaryTime to First Occurrence of Seizure Freedom During the Treatment

The time to first occurrence of seizure freedom was defined by the number of days after randomization to the first day of the first 28 consecutive days without seizures during the treatment. Time to first occurrence of 28 consecutive days of seizure freedom (days) during the treatment was calculated as date of first day of occurrence of 28 consecutive days of seizure freedom - Date of Randomization + 1.

Time frame:
From Baseline until the end of the Treatment (Week 25)
Reported as:
Median · Weeks
Time to First Occurrence of Seizure Freedom During the Treatment
WeeksPlaceboRozanolixizumab (RLZ)
Time to First Occurrence of Seizure Freedom During the Treatment0.1 (0.1 to 8.4)0.1 (0.1 to 8.3)
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP, whether or not related to the IMP. A TEAE was defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsens in intensity following exposure to treatment up to the end of the Treatment and including the 8-week (56 days) Safety-Follow Up (SFU).

Time frame:
From Baseline until the End of Study (Week 32)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsPlaceboRozanolixizumab (RLZ)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)100100

Adverse events

Collected over From Baseline until the End of Study (up to Week 32). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/6 (0%)3/6 (50%)6/6 (100%)
Rozanolixizumab (RLZ)0/6 (0%)3/6 (50%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboRozanolixizumab (RLZ)
COVID-19Infections and infestations0/61/6
Psoas abscessInfections and infestations1/60/6
BacteraemiaInfections and infestations0/61/6
Encephalitis autoimmuneNervous system disorders1/60/6
Peripheral sensory neuropathyNervous system disorders1/60/6
ManiaPsychiatric disorders0/61/6
Suicidal ideationPsychiatric disorders0/61/6
Deep vein thrombosisVascular disorders1/60/6
Most frequent other events
Showing 10 of 68
Most frequent other events
EventPlaceboRozanolixizumab (RLZ)
Oedema peripheralGeneral disorders0/64/6
DiarrhoeaGastrointestinal disorders1/63/6
Influenza like illnessGeneral disorders2/60/6
Alanine aminotransferase increasedInvestigations0/62/6
InsomniaPsychiatric disorders1/62/6
Rash maculo-papularSkin and subcutaneous tissue disorders2/60/6
LymphopeniaBlood and lymphatic system disorders1/61/6
Lacrimation increasedEye disorders1/60/6
Vision blurredEye disorders1/61/6
Abdominal painGastrointestinal disorders0/61/6

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS) which consisted of all enrolled study participants who were randomized to treatment arms.

Age, Continuous
Age, Continuous(Years)PlaceboRozanolixizumab (RLZ)Total
Mean60.7 ± 12.470.7 ± 11.465.7 ± 12.5
Age, Customized
Age, Customized(Participants)PlaceboRozanolixizumab (RLZ)Total
18 - <65 years314
65 - <85 years358
>=85 years000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRozanolixizumab (RLZ)Total
Female224
Male448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRozanolixizumab (RLZ)Total
White549
Missing123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRozanolixizumab (RLZ)Total
Not Hispanic or Latino549
Missing123
08

Study locations

27 sites
  • Aie001 50101
    Aurora, Colorado 80045-2541, United States
  • Aie001 50342
    Jacksonville, Florida 32224, United States
  • Aie001 50243
    Boston, Massachusetts 02114-3117, United States
  • Aie001 50047
    Boston, Massachusetts 02115, United States
  • Aie001 50104
    Rochester, Minnesota 55905, United States
  • Aie001 50298
    New York, New York 10016, United States
  • Aie001 50090
    Winston-Salem, North Carolina 27157, United States
  • Aie001 50311
    Cleveland, Ohio 44195, United States
  • Aie001 50304
    Dallas, Texas 75390-8869, United States
  • Aie001 30027
    Melbourne, Australia
  • Aie001 40123
    Brussels, Belgium
  • Aie001 40129
    Bordeaux, France
  • Aie001 40426
    Bron, France
  • Aie001 40364
    Lille, France
  • Aie001 40546
    Nancy, France
  • Aie001 40132
    Nice, France
  • Aie001 40019
    Paris, France
  • Aie001 40286
    Toulouse, France
  • Aie001 40515
    Berlin, Germany
  • Aie001 40249
    Kiel, Germany
  • Aie001 40695
    Pavia, Italy
  • Aie001 40567
    Roma, Italy
  • Aie001 40264
    Rotterdam, Netherlands
  • Aie001 40267
    Barcelona, Spain
  • Aie001 40341
    Málaga, Spain
  • Aie001 40168
    Nottingham, United Kingdom
  • Aie001 40163
    Oxford, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Mar 2024, 29 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
May 6, 2021
StartActual
Sep 27, 2021
Primary completionActual
Mar 8, 2024
CompletionActual
Apr 26, 2024
Results first posted
May 31, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04875975
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Sep 27, 2021
Primary completion
Mar 8, 2024
Completion
Apr 26, 2024
Results posted
May 31, 2025
Last update
May 31, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion